1,721,007 research outputs found
84: [Antibiotic preparation in operations on the large intestine. Experimental study] GF, Rollandi GA.
No full textVACOP-B Versus VACOP-B Plus Autologous Bone Marrow Transplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
No full text
[Antibiotic preparation in operations on the large intestine. Experimental study].
No full textA controlled study was mounted to assess the possible benefit of a single phlebo
administration of 600 mg lincomycin 1 hr prior to colon surgery, in addition to
the erythromycin + neomycin combination proposed by Nichols, as a means of
constituting a further pharmacological barrier to the spread of anaerobic
bacteria. The study currently comprises two groups of 15 patients fully
comparable with regard to pathology distribution and randomly assigned to the
E.N. and the E.N.L. protocol respectively. Six instances of septic complication
have been observed, five in the group prepared with E.N. and 1 prepared with
E.N.L. No significance can be attached to the different incidence of
complications in the two arms of the study, owing to the small number of cases
examined
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
No full text
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
No full textBackground: Standard methods to prevent chemotherapy-induced early menopause in young, breast cancer
patients are unavailable to date. Preclinical data has suggested that luteinising hormone-releasing hormone (LH-RH)
analogs given during treatment can decrease the gonado-toxicity induced by chemotherapy. This phase II study
aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy.
Patients and methods: Premenopausal patients received the LH-RH analog goserelin 3.6 mg every 4 weeks before
and during chemotherapy. According to two-stage optimal phase II Simon design, treatment was considered clinically
interesting if it was able to prevent menopause in 19 out of 29 patients of the study population. The resumption of
ovarian function was defined by a resumption of menstrual activity or by a follicle-stimulating hormone (FSH)
value £40 IU/l within 12 months after the last cycle of chemotherapy.
Results: Thirty patients were enrolled and 29 were evaluable. Median age was 38 years (range 29–47). All but one
patient received CEF regimen (cyclophosphamide, epirubicin, 5-fluorouracil). Resumption of menstrual activity was
observed in 21 patients (72%; 95% CI 52% to 87%) and a FSH value £40 IU/l in 24 patients (83%; 95% CI 63% to
93%). Menses resumption was observed in 16 out of 17 patients (94%) with age <40 years and in five out of
12 patients (42%) with age ‡40 years.
Conclusion: Goserelin given before and during chemotherapy may prevent premature menopause in the majority of
patients. The different success rate by age, however, indicates the need of a prospective evidence of the efficacy
of such a strateg
- …
